Get a Sample
Schedule a Meeting
Get a Sample
Table Of Content
December 2024
The global lymphedema diagnostics market size is calculated at USD 46.09 million in 2025 and is forecasted to reach around USD 70.52 million by 2034, accelerating at a CAGR of 4.84% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
The global lymphedema diagnostics market size accounted for USD 43.96 million in 2024 and is predicted to increase from USD 46.09 million in 2025 to approximately USD 70.52 million by 2034, expanding at a CAGR of 4.84% from 2025 to 2034. The market growth is attributed to the rising prevalence of cancer-related lymphedema and the increasing emphasis on early diagnosis. Advances in diagnostic technologies further support market growth.
The lymphedema diagnostics market refers to the global industry involved in the detection, assessment, and monitoring of lymphedema, a chronic condition characterized by abnormal accumulation of lymphatic fluid causing swelling, typically in the limbs. The market involves imaging technologies, bioimpedance spectroscopy, and physical measurement tools that help in early identification, severity grading, and treatment monitoring of lymphedema, particularly secondary lymphedema caused by cancer treatments, infections, or trauma. Accurate diagnosis is critical to prevent progression and improve quality of life.
The rise in cancer survivorship globally is driving high demand for superior lymphedema diagnostics, with early detection of secondary complications like lymphatic dysfunction being a top priority for clinicians. Imaging and measurement technologies used in lymphedema diagnosis, including lymphoscintigraphy, near-infrared fluorescence (NIRF) imaging, ultrasound, and bioimpedance spectroscopy (BIS), are key tools. These tools evaluate excess fluids and stagnation within lymphatic vessels to identify lymphedema symptoms at their earliest stages. Furthermore, the increasing awareness of the utility of these technologies, especially their incorporation into survivorship care plans, is expected to fuel market growth.
Artificial Intelligence is revolutionizing lymphedema diagnostics by significantly enhancing the accuracy, speed, and efficiency of clinical assessment. Real-time analysis of complex data using these technologies provides objective results, reducing the chance of misdiagnosis. AI improves image interpretation and detects anatomical changes often missed by traditional methods. AI is crucial for implementing continuous monitoring and early warning systems for high-risk patients. Moreover, integrating AI into diagnostic platforms accelerates research and development of smarter, data-driven technologies. AI algorithms can analyze medical images to detect subtle signs of lymphedema, such as fluid accumulation, lymphatic vessel abnormalities, and tissue changes, often with greater speed and accuracy than human analysis. This can lead to earlier and more precise diagnoses.
| Report Coverage | Details |
| Market Size by 2034 | USD 70.52 Million |
| Market Size in 2025 | USD 46.09 Million |
| Market Size in 2024 | USD 43.96 Million |
| Market Growth Rate from 2025 to 2034 | CAGR of 4.84% |
| Dominating Region | North America |
| Fastest Growing Region | Asia Pacific |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Diagnostic Technology, Application, End-User, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
How is the Increasing Prevalence of Cancer-Related Lymphedema Driving Demand for Early and Accurate Diagnostics?
The market is projected to be driven by the growing prevalence of cancer-related lymphedema. This increase is likely to boost the expansion of early and precise diagnostics. A rising number of breast, gynecologic, prostate, and head and neck cancers has led to more patients requiring surgical removal of lymph nodes or radiation therapy. Early-stage diagnosis has proven critical, especially in cancer management, to prevent progression to advanced stages.
The National Cancer Institute (NCI) indicates that lymphedema affects around 20-30% of breast cancer survivors in the United States after treatment. The growing need to manage long-term treatment complications in oncology care has increased the demand for scalable and reliable diagnostic tools in the healthcare industry worldwide. Additionally, the drive to minimize the risk of lasting damage to the lymphatic system further fuels the demand for lymphedema diagnostics for early detection. Furthermore, increased awareness among healthcare professionals and the public about lymphedema leads to more frequent screenings and diagnoses.
(Source: https://www.cancer.gov)
Limited Awareness and Inadequate Clinical Training Expected to Restrict Diagnostic Adoption
Limited awareness and clinical training are anticipated to hinder the growth of the lymphedema diagnosis market. In many regions, particularly in developing nations, healthcare professionals lack sufficient education in identifying and treating lymphedema. The absence of standardized diagnostic procedures and preliminary screening leads to underdiagnosis or misdiagnosis, especially in non-oncological cases. Even with technological advancements, the effectiveness of these tools is limited if frontline providers fail to integrate them into routine care. This lack of awareness significantly impedes the adoption of specialized diagnostic tools in general practice, thereby further restraining the market. Moreover, Advanced diagnostic technologies can be expensive, limiting their accessibility, particularly in resource-constrained settings.
How Are Surging Investments in Healthcare Infrastructure and Innovation Accelerating Growth in the Lymphedema Diagnostics Market?
Increasing investments in healthcare infrastructure and diagnostic innovation are projected to generate significant opportunities for market players. Both governments and individuals are increasing spending to improve the availability of diagnostic technologies in both rural and urban areas. Research and development in lymphatic imaging and fluid analysis technology has accelerated, leading to the introduction of compact devices incorporating AI. These advancements are experiencing quicker market adoption and broader clinical use across various care applications. Furthermore, the development of more accurate, non-invasive, and cost-effective diagnostic tools, such as advanced imaging techniques and point-of-care devices, is rising, opening up new opportunities in the market.
(Source: https://pmc.ncbi.nlm.nih.gov)
Why Did the Lymphoscintigraphy Segment Dominate the Market in 2024?
The lymphoscintigraphy segment dominated the lymphedema diagnostics market, accounting for a 40–45% share in 2024. This imaging technique has been increasingly used in clinical practices due to its reliability in visualizing lymphatic drainage patterns and obstructions. Hospitals and cancer centers favor lymphoscintigraphy because it effectively evaluates both primary and secondary lymphedema. The method’s suitability for nuclear medicine tools and its functional imaging capabilities enhance its applicability in post-cancer treatment scenarios. In 2024, a CDC-funded clinical trial demonstrated the procedure’s efficacy in monitoring changes in breast cancer patients’ lymphatic conditions over time. Moreover, the importance of lymphoscintigraphy in early diagnosis further boosts the demand for this diagnostic technology.
(Source: https://pubmed.ncbi.nlm.nih.gov)
The near-infrared fluorescence imaging (NIRF) segment is expected to grow at the fastest rate in the coming years. NIRF imaging offers real-time, in vivo visualization of superficial lymphatic structures using indocyanine green dye. This allows clinicians to monitor lymphatic flow without radiation exposure. Its minimal invasiveness and quick results make it suitable for both hospitals and outpatient settings.
Technological advances have led to portability and increased resolution, expanding its use globally. A 2024 FDA-supported pilot study highlighted NIRF imaging’s utility in early detection, particularly in post-operative lymphedema cases. Furthermore, NIRF imaging’s ability to improve treatment planning accuracy in complex lymphatic dysfunctions is expected to drive segment growth in the coming years.
(Source: https://pmc.ncbi.nlm.nih.gov)
What Made Primary Lymphedema Diagnosis the Dominant Segment in 2024?
The primary lymphedema diagnosis segment dominated the lymphedema diagnostics market with a 55-60% revenue share in 2024 because it is a condition present from birth or develops early in life, often requiring lifelong management. Early and accurate diagnosis is crucial for effective treatment and preventing complications. Diagnostic assessments of patients with unexplained limb edema and lymphatic formation irregularities are crucial. Experts have utilized innovative imaging and fluid evaluation methods to differentiate between primary lymphedema and other forms of chronic edema.
Clinical campaigns and studies have increased awareness of the hereditary nature of lymphatic disorders, leading to more early diagnoses. A 2024 study, funded by the National Institutes of Health and published in The New England Journal of Medicine, emphasized the use of genetic screening and lymphoscintigraphy in the diagnosis of early-onset primary lymphedema. Additionally, the focus on non-acquired lymphedema in adult, pediatric, and adolescent populations further supports this segment.
(Source: https://my.clevelandclinic.org)
(Source: https://www.ncbi.nlm.nih.gov)
The secondary lymphedema diagnosis segment is expected to grow at the fastest rate in the coming years due to rising cancer survivorship rates, leading to more cases following radiation therapy or lymph node dissection. Oncologists and rehabilitation specialists are increasingly incorporating diagnostic evaluations into post-treatment follow-up protocols. Additionally, increased federal funding for post-cancer rehabilitation programs, including routine lymphatic diagnostics, further supports the growth of this segment.
How Does the Hospitals Segment Dominate the Market in 2024?
The hospitals segment dominated the lymphedema diagnostics market, accounting for a 60% share in 2024, as these settings offer major lymphedema diagnostic procedures to cater to a broader patient base. Hospitals are the primary point of contact. The availability of advanced diagnostic tools in these settings attracts a large patient population. Doctors in hospitals regularly check patients for lymphatic complications, both in recovering cancer patients and those with chronic illnesses. Centralized care focuses on early detection and post-surgery care, supporting the use of diagnostic imaging techniques such as lymphoscintigraphy, ultrasound, and bioimpedance spectroscopy.
Clinical trials and collaborative research studies were also undertaken by the public and private hospitals, making them the center of primary diagnostics. The large patient inflow and investments in hospitals and clinics enable them to acquire and maintain modern diagnostic platforms, making them the most powerful end-user group globally. Hospitals are also crucial in providing access to lymphatic imaging, especially in low- and middle-income countries implementing cancer control measures, which further supports this segment.
The specialized lymphedema treatment centers segment is expected to grow at the fastest rate in the coming years. Specialized centers focus solely on lymphatic disorders, offering a comprehensive solution that includes diagnostics, therapy, and long-term follow-up. Technological advancements and the increased recognition of early-stage detection’s importance drive improved referrals to these specialized facilities.
In 2024, the National Institutes of Health (NIH) supported initiatives to enhance special lymphedema treatment centers in high-cancer-incidence areas. Clinical guidelines from The Lancet Oncology in 2024 recommended referring patients to specialized facilities for advanced imaging, such as near-infrared fluorescence (NIRF) and tissue dielectric constant (TDC) analysis. Furthermore, countries testing regional lymphedema centers observed improved outcomes in both urban and peri-urban populations, confirming their relevance in national health policies.
(Source: https://pmc.ncbi.nlm.nih.gov)
(Source: https://www.ouhealth.com)
What Made North America the Dominant Region in the Market?
North America dominated the lymphedema diagnostics market, capturing the largest revenue share in 2024. This is due to advanced healthcare infrastructure, strong oncology care networks, and the use of imaging technologies. The use of diagnostic tools in post-cancer treatment has propagated a steady demand from hospitals and clinics. The U.S. and Canada have incorporated procedures like lymphoscintigraphy, ultrasound, and bioimpedance spectroscopy into treatment models. There is high usage of telemedicine for remote monitoring and diagnosis, improving access to care, especially for patients in underserved areas.
In 2024, the BCRF estimated that approximately 4 million breast cancer survivors undergoing monitoring significantly drive secondary lymphedema diagnostics. The U.S. Food and Drug Administration (FDA) continues to approve innovative projects, such as AI-driven NIRF imaging systems, thereby increasing their availability in medicine. Major academic medical providers, including the Mayo Clinic and Johns Hopkins Medicine, have supported the clinical adoption and research, further fueling the market in this region.
(Source: https://www.bcrf.org)
Asia Pacific is expected to grow at the fastest rate in the market during the forecast period, driven by rising investments in advancing healthcare infrastructure and enhancing access to diagnostic services in major countries like China, India, Japan, and South Korea. With the increasing cancer incidence and growing clinician awareness, there is a high demand for imaging techniques, especially in clinics with oncology departments in major cities. Moreover, the growing aging population supports market expansion, as the aging population is more susceptible to chronic diseases, including those that can cause lymphedema.
A 2024 report by The Lancet Regional Health – Western Pacific highlights a significant rise in diagnostic imaging use for post-radiation confirmation in cancer patients. In India, the government’s national cancer care programs aim to increase access to ultrasound and bioimpedance equipment. Increased access to localized diagnostic technology and positive regulatory changes are boosting regional market growth through enhanced accessibility and affordability.
(Source: https://www.thelancet.com)
Europe is expected to experience notable growth in the coming years. The region’s strong regulatory environment, established cancer care infrastructure, and focus on early treatment have all contributed to the increased use of advanced diagnostic tools. Germany, France, the UK, and the Netherlands prioritized early lymphedema detection through national health systems, particularly for breast and gynecological cancer survivors. The European Society of Lymphology (ESL) 2024 emphasizes the use of bioimpedance spectroscopy and near-infrared fluorescence (NIRF) imaging in clinical procedures to enhance the validity of prognosis. These changes solidified Europe’s position as a key player in lymphedema management, thereby maintaining its market leadership.
(Source: https://www.vgm.com)
(Source: https://www.businesswire.com)
(Source: https://www.globenewswire.com)
By Diagnostic Technology
By Application
By End-User
By Region
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
December 2024
December 2024
June 2025
October 2024